X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Katie Koziara

Katie Koziara is a director of public affairs at PhRMA focusing on the organization’s executive visibility work and media relations strategy. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Katie earned her B.A. in Public Policy from the University of Michigan’s Ford School and is currently earning her M.A. in Fiction Writing from Johns Hopkins University.

Recent Posts

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

By Katie Koziara  |    January 19, 2023
This January, PhRMA joined health care leaders, investors, R&D experts and members of the media at the 2023 J.P. Morgan Health Care Conference in San Francisco, CA. During this week, we discussed...   Read More

Using traditional HTAs to determine coverage threatens patient access to medicine

By Katie Koziara  |    December 14, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

Traditional HTAs keep diverse patients out of the conversation

By Katie Koziara  |    December 7, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

How HTA-based price controls could worsen health outcomes and health disparities

By Katie Koziara  |    November 22, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

Traditional HTA methods treat everyone like the “average” patient

By Katie Koziara  |    November 7, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

Busting 3 Myths About Copay Coupons

By Katie Koziara  |    October 5, 2022
Insurer-imposed barriers like high deductibles and coinsurance shift the cost of life-saving care onto patients. Manufacturers and others have stepped forward to assist patients who face high...   Read More

Making coupons count for patients at the pharmacy counter

By Katie Koziara  |    August 25, 2022
Too many patients face high out-of-pocket costs for brand medicines, even when they have insurance.   Read More

Potential gene therapies bring hope to patients with sickle cell disease

By Katie Koziara  |    June 6, 2022
A recent analysis highlights how potential gene therapies have the potential to dramatically reduce income disparities for patients with sickle cell disease, leading to as much as $21,000 more in...   Read More

Study finds important health outcomes are not included in cost-effectiveness analyses for sickle cell, Alzheimer’s and MS treatments

By Katie Koziara  |    May 19, 2022
A new study from the Office of Health Economics (OHE) confirmed that the EQ-5D, a tool commonly used in health technology assessments (HTAs) often excludes outcomes important to patients and their...   Read More

Gene therapies can reduce treatment burden and costs for patients with blood disorders

By Katie Koziara  |    May 18, 2022
A new analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."